Back to top
more

GoodRx (GDRX)

(Real Time Quote from BATS)

$9.02 USD

9.02
310,596

+0.11 (1.24%)

Updated Jul 24, 2024 12:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

GoodRx Holdings, Inc. (GDRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for GoodRx Holdings, Inc. (GDRX) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

GoodRx Holdings, Inc. (GDRX) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 16.67% and 1.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Teladoc's (TDOC) BetterHelp Faces FTC Hurdle, to Pay $7.8M

by Zacks Equity Research

Teladoc's (TDOC) BetterHelp business is expected to continue implementing more comprehensive privacy standards.

GoodRx Holdings, Inc. (GDRX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 40% and 3.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Select Medical (SEM) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Select Medical (SEM) delivered earnings and revenue surprises of -33.33% and 2.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Life Time Group Holdings, Inc. (LTH) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Life Time Group Holdings, Inc. (LTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Wall Street Analysts Think GoodRx Holdings, Inc. (GDRX) Could Surge 97%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 97.4% upside potential for GoodRx Holdings, Inc. (GDRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

GDRX or LHCG: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GDRX vs. LHCG: Which Stock Is the Better Value Option?

GoodRx Holdings, Inc. (GDRX) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of 75% and 1.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aurora Cannabis (ACB) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Continued strength in Aurora Cannabis' (ACB) domestic adult recreational segment is expected to have driven Q1 sales.

TRxADE (MEDS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

TRxADE (MEDS) delivered earnings and revenue surprises of 50% and 27.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.

What's in Store for Shockwave Medical (SWAV) in Q3 Earnings?

by Zacks Equity Research

Shockwave Medical's (SWAV) third-quarter results are likely to reflect solid performance of its IVL system across geographies.

    Earnings Preview: Agiliti (AGTI) Q3 Earnings Expected to Decline

    by Zacks Equity Research

    Agiliti (AGTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    ModivCare (MODV) Q3 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    ModivCare (MODV) delivered earnings and revenue surprises of 6.62% and 9.98%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    What Awaits Lantheus Holdings (LNTH) This Earnings Season?

    by Zacks Equity Research

    Lantheus Holdings' (LNTH) third-quarter results are likely to reflect solid top line results on the back of robust product adoption.

    AMN Healthcare (AMN) to Post Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    AMN Healthcare's (AMN) third-quarter results are likely to reflect solid demand across all its segments.

    GoodRx Holdings, Inc. (GDRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    by Zacks Equity Research

    GoodRx Holdings, Inc. (GDRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Why GoodRx Holdings, Inc. (GDRX) Could Beat Earnings Estimates Again

    by Zacks Equity Research

    GoodRx Holdings, Inc. (GDRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?

    by Zacks Equity Research

    Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

    NextGen Healthcare (NXGN) Q2 Earnings Beat, FY23 View Up

    by Zacks Equity Research

    NextGen's (NXGN) second-quarter fiscal 2023 results reflect strength in both its revenue sources.

    Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.

    Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.

    Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

    by Zacks Equity Research

    Ecolab's (ECL) third-quarter results are likely to reflect continued strength in its Global Industrial segment.

    Here's Why GoodRx Holdings, Inc. (GDRX) Looks Ripe for Bottom Fishing

    by Zacks Equity Research

    GoodRx Holdings, Inc. (GDRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.